Related Experiment Videos
Effective high-dose intravenous gammaglobulin therapy for passive immune thrombocytopenia in the neonate
European Journal of Pediatrics
|January 1, 1987
Insights
Polyethylene glycol-conjugated (PEG) gammaglobulins effectively treated thrombocytopenia in a newborn. The treatment rapidly increased platelet counts, resolving the condition within 10 days.
Area of Science:
- Neonatal Medicine
- Immunology
- Hematology
Background:
- Idiopathic thrombocytopenic purpura (ITP) in mothers can pose risks to newborns, potentially causing low platelet counts.
- Neonatal thrombocytopenia requires prompt and effective management to prevent complications.
Observation:
- A newborn with thrombocytopenia, born to a mother with ITP, was treated with PEG-gammaglobulins.
- The infant received 400 mg/kg/day of PEG-gammaglobulins for the first five days of life.
Findings:
- Platelet count increased significantly from 15 x 10(9)/l to 200 x 10(9)/l within 10 days.
- Sustained therapeutic levels of platelets were maintained after the initial 10-day period.
Implications:
- PEG-gammaglobulins demonstrate efficacy in treating neonatal thrombocytopenia secondary to maternal ITP.
- This treatment offers a potential therapeutic strategy for managing similar cases, improving neonatal outcomes.
Abstract:
The second child of a mother with idiopathic thrombocytopenic purpura was given 400 mg/kg per day polyethylenglycol-treated gammaglobulins during the first 5 days of life. Thrombocytes increased from 15 X 10(9)/l to 200 X 10(9)/l within 10 days and remained at this level afterwards.